Pesquisar
Regenxbio Inc
RGNXAdicionar à lista de desejos
13.280USD
+0.190+1.45%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
686.54MValor de mercado
PerdaP/L TTM
Mais detalhes de Regenxbio Inc Empresa
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Informações de Regenxbio Inc
Código da empresaRGNX
Nome da EmpresaRegenxbio Inc
Data de listagemSep 17, 2015
CEOSimpson (Curran M)
Número de funcionários353
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço9804 Medical Center Drive
CidadeROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Telefone12405528181
Sitehttps://regenxbio.com/
Código da empresaRGNX
Data de listagemSep 17, 2015
CEOSimpson (Curran M)
Executivos da empresa Regenxbio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
28.86K
+33.98%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Perguntas frequentes
Quem são os cinco principais acionistas de Regenxbio Inc?
Os cinco principais acionistas de Regenxbio Inc são: Mr. Mitchell Chan
Quantas instituições possuem ações da Regenxbio Inc (RGNX)?
Em 2026Q1, 410 instituições possuíam ações da Regenxbio Inc, com valor de mercado aproximado de 45.28M, representando 87.72% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3475301.00.